Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (281-290 of 377) with videos related to

Pageof 38
Sort By:
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The Lancet. Oncology|December 14, 2017
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyCarsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, et al.
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
JAMA Oncology|July 18, 2017
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical TrialEric Hahnen, Bianca Lederer, Jan Hauke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.
Therapeutic Advances in Medical Oncology|June 5, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy Dennis J Slamon, Peter A Fasching, Sara Hurvitz, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 1 - Prevention and Early StagesElmar Stickeler, Bahriye Aktas, Annika Behrens, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and BiomarkersNina Ditsch, Elmar Stickeler, Annika Behrens, et al.
Pageof 38

Showing results (281-290 of 377) with videos related to

Sort By:
Pageof 38
Geburtshilfe Und Frauenheilkunde|July 29, 2022
Update Breast Cancer 2022 Part 1 - Early Stage Breast CancerManfred Welslau, Volkmar Müller, Diana Lüftner, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
The Lancet. Oncology|December 14, 2017
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapyCarsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, et al.
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
JAMA Oncology|July 18, 2017
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical TrialEric Hahnen, Bianca Lederer, Jan Hauke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.
Therapeutic Advances in Medical Oncology|June 5, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy Dennis J Slamon, Peter A Fasching, Sara Hurvitz, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 1 - Prevention and Early StagesElmar Stickeler, Bahriye Aktas, Annika Behrens, et al.
Geburtshilfe Und Frauenheilkunde|May 26, 2021
Update Breast Cancer 2021 Part 2 - Advanced Stages, Long-Term Consequences and BiomarkersNina Ditsch, Elmar Stickeler, Annika Behrens, et al.
Pageof 38